3M
As of the edition of 20 October 2026, 3M runs 20 drugs, 20 of them marketed; it is on route A at 0 targets and on route B at 6 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 2 company names in this family.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 20 |
| Total | 20 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Epinephrine | none listed | 23 |
| Albuterol | none listed | 2 |
| Heparin | none listed | 5 |
| Imiquimod | none listed | 2 |
| Beclomethasone dipropionate | none listed | 3 |
| Flecainide | none listed | 0 |
| Heparin sodium | none listed | 3 |
| Isoproterenol | none listed | 3 |
| Methenamine | none listed | 0 |
| Orphenadrine | none listed | 2 |
| Edetate calcium disodium anhydrous | none listed | 0 |
| Chlophedianol | none listed | 0 |
| Diethylpropion | none listed | 1 |
| Hexachlorophene | none listed | 0 |
| Edetate disodium anhydrous | none listed | 0 |
| Ergotamine | none listed | 6 |
| Alkavervir | none listed | 0 |
| Alseroxylon | none listed | 5 |
| Pirbuterol | none listed | 1 |
| Ytterbium pentetate | none listed | 0 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 6 targets.
All 6 rows on route A or B
In the product6 company-target rows on route A or B; 3 are not shown here, and no score is.
See all 6 targets where 3M needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.